11/21/2025
The FDA wants to cut prescription drug costs by fast-tracking biosimilars (cheaper generics for biologics). Great news for your wallet!
But the U.S. Patent Office (USPTO) is making it nearly impossible for these companies to challenge the legal patents that block them from launching.
This bureaucratic clash is the key reason cheaper drugs stay off the market for years.
Find out how the "patent thicket" is defeating the FDA's cost-saving efforts. 👇
🔗 https://pharmaleaders.com/biosimilar-boom-on-hold-fdas-plan-confronts-patent-office-resistance/
The Food and Drug Administration (FDA) is taking major steps to speed up the approval and reduce the